You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
AAV2-ASPA-Based Metabolic Intervention for Alzheimer's Disease
SBC: ASKLEPIOS BIOPHARMACEUTICAL, INC. Topic: NIAAbstract We propose to initiate preclinical development of a gene therapeutic targeted to Alzheimer's Disease. The World Health Organization's and Alzheimer's Disease International's report on Dementia (2012) recognizes that the global burden of AlzheimerDisease is forecast to worsen significantly with prevalence predicted to double every 20 years. Interventions that could prov ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A Millimeter-wave Tunable Cavity for Ultra-sensitive Solids and Liquids DNP-NMR at Low Budget
SBC: DOTY SCIENTIFIC, INC. Topic: NIA? DESCRIPTION (provided by applicant): NMR is probably the most powerful and widely used analytical technique for structure determination and function elucidation of molecules of all types, but it suffers from low sensitivity, particularly for insoluble biological macromolecules. Dynamic Nuclear Polarization (DNP) with Magic Angle Spinning (MAS) has recently demonstrated S/N gains exceeding t ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel therapeutic approach for Acute Lung Injury/ARDS
SBC: BIOMARCK PHARMACEUTICALS, LTD Topic: NHLBIDESCRIPTION (provided by applicant): The objective of the proposed project is to advance the development of novel peptides targeting MARCKS (Myristoylated Alanine-Rich C Kinase Substrate) protein as platform drug molecules for the treatment of Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), thereby providing the first pharmacologic therapeutic for this ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Automated, Web Based Software Development for Predictive QSAR Modeling
SBC: PHORCAST, INC. Topic: N/ADESCRIPTION (provided by applicant): In the course of previous basic studies in our laboratory, we have developed statistically significant and robust Quantitative Structure-Activity Relationships (QSAR) methodologies, which incorporate rigorous validation procedures and lead to models with a high predictive power and practical utility. The methodologies are built upon the similarity principle, i. ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Blockade of NF-kappaB for Prevention/Treatment of GVHD
SBC: THERALOGICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Allogeneic stem cell transplantation (allo-SCT) is potentially curative therapy for a patients suffering from leukemia, lymphoma and multiple myeloma. However, the problems associated with graft-versus-host disease (GVHD) have greatly limited the use of allo-SCT to patients with either an HLA-identical family member or unrelated donor in many transplant centers ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Cell therapy of diabetes using broad spectrum multipotent stem cells
SBC: PLUREON CORP. Topic: N/ADESCRIPTION (provided by applicant): Transplantation of insulin-producing cells in many diabetes patients potentially would restore normal glucose homeostasis and prevent the severe long-term complications of the disease. However, the scarcity of donated pancreata currently limits transplantation of the whole organ or of isolated pancreatic islets to a tiny fraction of those patients who might ben ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Development and in vitro validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 105DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antigen Capture Assay for Babesia microti
SBC: BIOPEPTIDES CORP Topic: NIAIDDESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
SBC: VASCULAR PHARMACEUTICALS Topic: N/ADESCRIPTION (provided by applicant): The long term objective of the proposed studies is to develop a monoclonal antibody that can be administered safely to patients with diabetes to determine if it can inhibit atherosclerosis. Insulin-like growth factor-l (IGF-I) has been implicated in initiating the proliferative phase of atherosclerotic lesion development but inhibiting IGF-I receptor activity m ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Development of fluorescence-based receptor binding assays for the detection
SBC: SEATOX RESEARCH INC Topic: NIEHSDESCRIPTION (provided by applicant): Harmful algal blooms (HABs) are becoming frequent occurrences off the coasts of the United States, particularly in coastal waters of New England, the Gulf of Mexico, and the Pacific Ocean. Historically, HABs have beenassociated with fish kills and marine mammal mortalities; however, their effects on human health and economic loss due to HAB contamination of se ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health